ロード中...
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. I...
保存先:
| 出版年: | Transl Lung Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7653116/ https://ncbi.nlm.nih.gov/pubmed/33209626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-896 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|